BMS-833923

BMS-833923 (XL-139) is an orally biocompatible Smoothened (Smo) inhibitor with anti-tumor activity. It can inhibit the binding of BODIPY cyclopamine to SMO in a dose-dependent manner with an IC50 of 21 nM[1].

Product Specifications

CAS Number

[1059734-66-5]

Product Name Alternative

XL-139

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Smo

Type

Reference compound

Related Pathways

Apoptosis; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bms-833923.html

Concentration

10mM

Purity

99.82

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC(CNC)=CC=C1C)C2=CC=C(NC3=NC(C4=CC=CC=C4)=C5C=CC=CC5=N3)C=C2

Molecular Formula

C30H27N5O

Molecular Weight

473.57

Precautions

H302, H315, H319, H335

References & Citations

[1]Steven B, et al. Abstract B192: Preclinical characterization of BMS-833923 (XL139), a hedgehog (HH) pathway inhibitor in early clinical development. Molecular Cancer Therapeutics: December 2009; Volume 8, Issue 12, Supplement 1.|[2]Du J, et al. Disruption of SHH signaling cascade by SBE attenuates lung cancer progression and sensitizes DDP treatment. Sci Rep. 2017 May 15;7 (1) :1899. |[3]AlMuraikhi N, et al. Hedgehog Signaling Inhibition by Smoothened Antagonist BMS-833923 Reduces Osteoblast Differentiation and Ectopic Bone Formation of Human Skeletal (Mesenchymal) Stem Cells. Stem Cells Int. 2019 Nov 21;2019:3435901. |[4]Gu D, et al. Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis. Cancers (Basel) . 2018 Oct 26;10 (11) :403. |[5]Riedlinger D, et al. Hedgehog pathway as a potential treatment target in human cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2014 Aug;21 (8) :607-15.